^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Gastroesophageal Junction Adenocarcinoma)
    New
    Excerpt:
    Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer treatment for their metastatic disease.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

    Excerpt:
    ...HER2 positive defined as IHC2+ and FISH amplification ratio ≥2 or IHC3+ 5....
    Trial ID:
    HERES
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Case Report: Herceptin as a Potentially Valuable Adjuvant Therapy for a Patient With Human Epidermal Growth Factor Receptor 2-Positive Advanced Esophageal Squamous Cell Carcinoma

    Published date:
    02/01/2021
    Excerpt:
    We reported a patient with HER2-positive ESCC who received trastuzumab combined with chemotherapy and who experienced over 6 months PFS and 19 months OS.
    DOI:
    10.3389/fonc.2020.600459